FDA Adverse Event Injury Summary report: N

ASR UNI FEMORAL IMPL SIZE 49

MDR report key: 2163067 · Received July 8, 2011

Report

Report Number
1818910-2011-12432
Event Type
Injury
Date Received
July 8, 2011
Report Date
January 9, 2013
Manufacturer
DEPUY INTERNATIONAL, LTD.
Product Code
KWA
PMA / PMN Number
PK040627
Removal / Correction Number
Z-1749/1816-2011
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IN, US
Reporter Occupation
ATTORNEY

Narratives

Additional Manufacturer Narrative · 1

THE ASR PLATFORM WAS VOLUNTARILY RECALLED FROM THE MARKET IN AUGUST 2010, AND THE ASR PRODUCT CODES ARE NOW CONSIDERED INACTIVE. FURTHER INVESTIGATION OF THIS INDIVIDUAL INCIDENT WILL NOT BE UNDERTAKEN, AS THERE IS AN ONGOING INVESTIGATION REGARDING THE ROOT CAUSE(S) AND/OR CORRECTIVE ACTIONS. (B)(4).DEPUY CONSIDERS THE INVESTIGATION CLOSED AT THIS TIME. SHOULD THE PRODUCT AND/OR ADDITIONAL INFORMATION BE RECEIVED, THE INVESTIGATION WILL BE RE-OPENED.

Additional Manufacturer Narrative · 1

DEPUY STILL CONSIDERS THIS INVESTIGATION CLOSED.

Additional Manufacturer Narrative · 1

THIS COMPLAINT IS STILL UNDER INVESTIGATION. DEPUY WILL NOTIFY THE FDA OF THE RESULTS OF THIS INVESTIGATION ONCE IT HAS BEEN COMPLETED.

Description of Event or Problem · 1

LITIGATION PAPERS ALLEGE: ON (B)(6) 2006, PATIENT WAS IMPLANTED WITH A DEPUY ASR HIP ON HIS LEFT SIDE. IN (B)(6) 2008, PATIENT HAD TO UNDERGO A REVISION SURGERY DUE TO PAIN IN HIS LEFT HIP. DURING THE SURGERY, THE SURGEON FOUND A GOLF-BALL SIZED CYST AND SYNOVITIS, INDICATING METALLOSIS.

Description of Event or Problem · 1

(B)(4) 2012 - PLAINTIFF¿S PRELIMINARY DISCLOSURE FORM WAS RECEIVED, WHICH IDENTIFIED DOR AND PART/LOT INFORMATION. THE COMPLAINT AND ASSOCIATED MDRS WERE UPDATED. THERE WAS NO NEW INFORMATION THAT WOULD CHANGE THE OUTCOME OF THE INVESTIGATION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 ASR UNI FEMORAL IMPL SIZE 49 TOTAL HIP REPLACEMENT KWA DEPUY INTERNATIONAL, LTD. NA 2164319

Patients

Seq Age Sex Outcome Treatment
1 NA Required Intervention